Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety
Status:
Completed
Trial end date:
2021-01-05
Target enrollment:
Participant gender:
Summary
This will be a Phase 1, open label, imaging study of radiochemical and radiation safety in
healthy volunteers. Using positron emission tomography (PET) and in-line computed tomography
(CT), the whole body (WB) biokinetics of Carbon-11 butanol will be quantified with serial
scans acquired every 3 minutes for two hours. Vital signs (VS), electrocardiograms (ECGs) and
clinical laboratory tests of intrernal organ function will be acquired before and at several
timepoints after administration of the radiopharmaceutical. Radiation exposures will be
estimated with the MIRD Formalism.